Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2012

View Archived Issues

Merck & Co. presents new phosphodiesterase 10A inhibitors

Novel compounds for cancer patented

Photoreceptor-directed gene therapy shows promise to treat X-linked retinitis pigmentosa

New clinical results presented on Ad3-hTERT-E1A

IND cleared for phase I study of peptide to prevent dental caries

Shionogi divulges new treatments for Alzheimer's disease

ImmunoGen reports novel antibodies and immunoconjugates

Researchers at Glenmark Pharmaceuticals design new MPGES-1 inhibitors

Ensemble Therapeutics announces new collaboration

Lu-AE-58054 study meets primary endpoint

Andromeda peptide product receives FDA orphan drug status

New therapeutic approach to respiratory allergy presented

Acacia Pharma announces encouraging clinical results on APD-421

NeuroSearch reports on multiple-ascending-dose Huntexil trial

Oncos Therapeutics begins phase I study of oncolytic adenovirus

First-in-human trial of Bionor's second therapeutic HIV vaccine set to launch

Cytotoxic T lymphocytes expressing Epstein-Barr virus antigen administered to patients with lymphoma

Medivir cathepsin K inhibitor enters the clinic

Nuvo Research and Paladin Labs enter Canadian license agreement

ValiRx reports preclinical data on VAL-201

Janssen receives complete response letter regarding new Prezista tablet

FDA accepts filing of NDA for Kynamro

BMS forms international immuno-oncology collaboration with academic institutions

Advaxis completes enrollment in ADXS-HPV study

FDA validates NDA for Sitavig

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...